TC BioPharm (NASDAQ: TCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies for cancer and other indications, today announced its sponsored research agreement with Carnegie Mellon University. Under the agreement, TC BioPharm is partnering with Dr. Wei Wu, a faculty member in the Ray and Stephanie Lane Computational Biology Department within the university’s School of Computer Science, and her lab to explore the potential use of artificial intelligence (“AI”) to enhance the donor selection and matching processes.

“Dr. Wu and her laboratory are helping us tackle another ‘big problem’ with this endeavor, which has the potential to revolutionize both the donor selection and matching processes. An issue the cell therapy industry faces as a whole is donor variability as well as how to more accurately predict outcomes and responses between donors and patients. Finding a solution for how to select the best donors for allogeneic cell therapies to generate the best product, and also how to match the best cell therapy and donor to the best patient beyond the current HLA matching process, represents a massive opportunity from a market perspective and also would have far-reaching applications for CDMOs and other industry players,” said Bryan Kobel, CEO of TC BioPharm.

To view the full press release, visit https://ibn.fm/V7ZHS

About TC BioPharm Holdings PLC

TC BioPharm is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line – Phase 2b/3 pivotal trial for OmnImmune(R) in treatment of acute myeloid leukemia using the company’s proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. For more information about the company, visit www.tcbioparm.com.

NOTE TO INVESTORS: The latest news and updates relating to TCBP are available in the company’s newsroom at https://ibn.fm/TCBP

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN